SINOMED(SH:688108) Sou Hu Cai Jing·2025-10-30 23:24Core Insights - Sino Medical (688108.SH) reported a total revenue of 364 million yuan for Q3 2025, ranking 84th among disclosed peers [1] - The net profit attributable to shareholders was 21.12 million yuan, placing the company 87th among its peers [1] - The net cash inflow from operating activities was 83.97 million yuan [1] Financial Metrics - The latest debt-to-asset ratio is 30.40%, ranking 99th among disclosed peers, an increase of 1.01 percentage points from the previous quarter and 0.31 percentage points from the same period last year [3] - The latest gross profit margin stands at 65.70% [3] - The return on equity (ROE) is 2.34%, ranking 81st among disclosed peers [3] - The diluted earnings per share (EPS) is 0.05 yuan, ranking 97th among peers [3] - The total asset turnover ratio is 0.28 times [3] - The inventory turnover ratio is 1.30 times, ranking 76th among disclosed peers [3] Shareholder Information - The number of shareholders is 29,400, with the top ten shareholders holding a total of 135 million shares, accounting for 32.44% of the total share capital [3] - The largest shareholder is Tianjin Weixin Sunshine Enterprise Management Consulting Co., Ltd., holding 17.2% [3] - Other notable shareholders include Guo Yanchao (5.01%) and Tianjin Sunshine Guangye Enterprise Management Partnership (2.55%) [3]